![June 2023 FDA Watch](https://www.g2intelligence.com/wp-content/uploads/2023/05/June23.LIR_.FDAWatch-iStock-1100-x-800-1080x675.jpg)
June 2023 FDA Watch
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
The end of the COVID-19 public health emergency on May 11 also brings certain flexibilities for labs and other providers to an end.
CMS recently issued long-awaited guidance on post-PHE changes to Medicare coverage of SARS-CoV-2 diagnostic tests.
Lucira has fallen on hard times since it secured the first FDA EUA for an at-home COVID-19 test in November 2020.